Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human Remove Human filter Veterinary (1) Apply Veterinary filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

Summaries of opinion Remove Summaries of opinion filter Referrals Remove Referrals filter Direct healthcare professional communication Remove Direct healthcare professional communication filter European public assessment reports (EPAR) (430) Apply European public assessment reports (EPAR) filter Withdrawn applications (32) Apply Withdrawn applications filter Paediatric investigation plans (29) Apply Paediatric investigation plans filter Orphan designations (28) Apply Orphan designations filter

Product number

Opinion status

Positive (8) Apply Positive filter

Application type

Initial authorisation (6) Apply Initial authorisation filter Post-authorisation (2) Apply Post-authorisation filter

Date of opinion

From:

To:

Referral name

Referral status

European Commission final decision (5) Apply European Commission final decision filter Procedure started (1) Apply Procedure started filter

Referral safety status

Yes (3) Apply Yes filter

Referral type

Article 20 procedures (3) Apply Article 20 procedures filter Article 31 referrals (3) Apply Article 31 referrals filter

Referral reference number

Referral decision making model

PRAC-CAT-CHMP-EC (1) Apply PRAC-CAT-CHMP-EC filter PRAC-CHMP-EC (3) Apply PRAC-CHMP-EC filter

Referral authorisation model

Centrally and nationally authorised products (mixed) (3) Apply Centrally and nationally authorised products (mixed) filter Centrally authorised product(s) (3) Apply Centrally authorised product(s) filter

Referral PRAC recommendation

Risk minimisation measures (2) Apply Risk minimisation measures filter Variation (1) Apply Variation filter

Referral procedure start date

From:

To:

Referral PRAC recommendation date

From:

To:

Decision date

From:

To:

ATC code

Medicine type

Biosimilar Remove Biosimilar filter Conditional approval Remove Conditional approval filter Generic Remove Generic filter Accelerated assessment (3) Apply Accelerated assessment filter Additional monitoring (65) Apply Additional monitoring filter Exceptional circumstances (5) Apply Exceptional circumstances filter Orphan medicine (24) Apply Orphan medicine filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

28 results

Remove all filtersRemove all filters

Keyword Remove keyword

Medicine type Conditional approval Remove Conditional approval filter Biosimilar Remove Biosimilar filter Generic Remove Generic filter

Medicine Referrals Remove Referrals filter Summaries of opinion Remove Summaries of opinion filter Direct healthcare professional communication Remove Direct healthcare professional communication filter

Categories Human Remove Human filter

Sort by

List item

Referral: Renin-angiotensin-system (RAS)-acting agents

captopril, imidapril, zofenopril, candesartan, delapril, telmisartan, aliskiren, moexipril, enalapril, valsartan, fosinopril, irbesartan, perindopril, quinapril, ramipril, eprosartan, olmesartan, trandolapril, losartan, azilsartan, lisinopril, spirapril, benazepril, cilazapril, associated names: Tolucombi, Telmisartan Teva, Telmisartan Teva Pharma, Tolura, Onduarp, Twynsta, Actelsar HCT, Kinzalkomb, MicardisPlus, PritorPlus, Copalia HCT, Dafiro HCT, Exforge HCT, Rasilamlo, Rasilez, Rasilez HCT, Rasitrio, Edarbi, Ipreziv, Aprovel, Ifirmasta (previously Irbesartan Krka), Irbesartan Teva, Irbesartan Zentiva (previously Irbesartan Winthrop), Karvea, Sabervel, CoAprovel, Ifirmacombi, Irbesartan/Hydrochlorothiazide Teva, Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop), Karvezide, Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG), Micardis, Pritor, Telmisartan Actavis, Article 31 referrals
Status: European Commission final decision, opinion/position date: 22/05/2014, EC decision date: 04/09/2014, Last updated: 08/10/2014
List item

Direct healthcare professional communication (DHPC): Polivy (polatuzumab vedotin) 140 mg powder for concentrate for solution for injection: Important information on plastic vial flip-off cap colour

Active substance: polatuzumab vedotin, DHPC type: Quality defect, Last updated: 04/05/2020
List item

Summary of opinion: Vegzelma

bevacizumab, opinion date: 23/06/2022, Positive, Last updated: 21/06/2022

28 results

Referral: Renin-angiotensin-system (RAS)-acting agents

Direct healthcare professional communication (DHPC): Polivy (polatuzumab vedotin) 140 mg powder for concentrate for solution for injection: Important information on plastic vial flip-off cap colour

Summary of opinion: Vegzelma